A study led by Dr. Monika E. Hegi, MD, Ph.D. and European Organization for Research and Treatment of Cancer (EORTC) headquarters team (Felix Oppong Msc, Dr. Thierry Gorlia, Ph.D.) reveals that elderly glioblastoma patients with truly unmethylated MGMT promoter do not benefit from temozolomide (TMZ) treatment, challenging current treatment protocols and paving the way for more personalized therapies.
The study reanalyzed data from the CE.6 and pooled Nordic/NOA-08 trials, involving 687 patients, to assess the impact of MGMT promoter methylation on TMZ treatment efficacy.
Using a specific cutoff established through a pooled analysis of four clinical trials, the research confirmed that patients with truly unmethylated MGMT promoter derived no benefit from TMZ, whether administered alone or in combination with radiotherapy (RT).
This finding underscores the necessity of using validated MGMT promoter methylation assays to accurately identify patients who will not benefit from TMZ, thereby reducing unnecessary toxicity and allowing for the exploration of more promising treatment options. The research is published in the journal Neuro-Oncology.
The significance of this study lies in its potential to transform the treatment landscape for elderly glioblastoma patients. By accurately identifying patients who will not benefit from TMZ, health care providers can avoid undue toxicity and focus on more effective treatment strategies.
The European Organization for Research and Treatment of Cancer (EORTC) and other collaborating organizations emphasize the importance of stratified patient management to improve outcomes without compromising patient safety.
“This study represents a pivotal moment in the treatment of glioblastoma, particularly for our older adult patients,” says Monika E. Hegi, Ph.D. “By refining our approach to patient selection, we can significantly enhance treatment efficacy and patient quality of life.”
These findings highlight the critical role of MGMT promoter methylation in guiding treatment decisions for glioblastoma, offering a path toward more personalized and effective therapies.
More information:
Monika E Hegi et al, No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly glioblastoma patients, Neuro-Oncology (2024). DOI: 10.1093/neuonc/noae108
Provided by
European Organisation for Research and Treatment of Cancer (EORTC)
Citation:
New insights into glioblastoma treatment for elderly patients (2024, October 9)
retrieved 9 October 2024
from https://medicalxpress.com/news/2024-10-insights-glioblastoma-treatment-elderly-patients.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
